PHLI Terminates Satietrol

PHLI Terminates Satietrol® Licensing Agreement
PacificHealth Laboratories, Inc. (PHLI), Woodbridge, NJ, has reacquired all rights to Satietrol® following the termination of a license agreement with GlaxoSmithKline (GSK), Research Triangle Park, NC. Satietrol is an appetite control product specifically designed to activate cholecystokinin (CCK), a peptide released by the body after eating that plays an important role in controlling ap­petite. GSK owns approximately 8.9% of the outstanding common stock of PHLI and has not indicated to PHLI any current intentions to decrease its holdings although GSK has no binding commitment with respect to the holding or sale of their shares in PHLI.